Evidence map›Paper›PMID 35073457›Full record

ArticleHLA2022

Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants.

Irantzu Anzar, Angelina Sverchkova, Pubudu Samarakoon, Espen Basmo Ellingsen, Gustav Gaudernack, Richard Stratford, Trevor Clancy

Open access · hybridAbstract read
In one paragraph

Article in HLA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Irantzu AnzarNEC OncoImmunity AS, Oslo Cancer Cluster, Oslo, Norway.
Angelina SverchkovaNEC OncoImmunity AS, Oslo Cancer Cluster, Oslo, Norway.
Pubudu SamarakoonNEC OncoImmunity AS, Oslo Cancer Cluster, Oslo, Norway.
Espen Basmo EllingsenUltimovacs ASA, Oslo Cancer Cluster, Oslo, Norway.
Gustav GaudernackUltimovacs ASA, Oslo Cancer Cluster, Oslo, Norway.
Richard StratfordNEC OncoImmunity AS, Oslo Cancer Cluster, Oslo, Norway.
Trevor ClancyNEC OncoImmunity AS, Oslo Cancer Cluster, Oslo, Norway.ORCID 0000-0001-9896-0613
Cancer Registry of Norway · NOUltimovacs (Norway) · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate and full-length typing of the HLA region is important in many clinical and research settings. With the advent of next generation sequencing (NGS), several HLA typing algorithms have been developed, including many that are applicable to whole exome sequencing (WES). However, most of these solutions operate by providing the closest-matched HLA allele among the known alleles in IPD-IMGT/HLA Database. These database-matching approaches have demonstrated very high performance when typing well characterized HLA alleles. However, as they rely on the completeness of the HLA database, they are not optimal for detecting novel or less well characterized alleles. Furthermore, the database-matching approaches are also not adequate in the context of cancer, where a comprehensive characterization of somatic HLA variation and expression patterns of a tumor's HLA locus may guide therapy and clinical outcome, because of the pivotal role HLA alleles play in tumor antigen recognition and immune escape. Here, we describe a personalized HLA typing approach applied to WES data that leverages the strengths of database-matching approaches while simultaneously allowing for the discovery of novel HLA alleles and tumor-specific HLA variants, through the systematic integration of germline and somatic variant calling. We applied this approach on WES from 10 metastatic melanoma patients and validated the HLA typing results using HLA targeted NGS sequencing from patients where at least one HLA germline candidate was detected on Class I HLA. Targeted NGS sequencing confirmed 100% performance for the 1st and 2nd fields. In total, five out of the six detected HLA germline variants were because of Class I ambiguities at the third or fourth fields, and their detection recovered the correct HLA allele genotype. The sixth germline variant let to the formal discovery of a novel Class I allele. Finally, we demonstrated a substantially improved somatic variant detection accuracy in HLA alleles with a 91% of success rate in simulated experiments. The approach described here may allow the field to genotype more accurately using WES data, leading to the discovery of novel HLA alleles and help characterize the relationship between somatic variation in the HLA region and immunosurveillance.

Indexed as

HLA AntigensNeoplasmsAllelesGenotypeHigh-Throughput Nucleotide SequencingHistocompatibility TestingHumansSequence Analysis, DNAHLA AntigensHLA typingHLA variant callingnovel HLA allele discoverytumor-specific HLA variantswhole exome sequencing (WES)

Identifiers

PMID35073457
PMCPMC9546058
OpenAlexW4207080911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.